<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841775</url>
  </required_header>
  <id_info>
    <org_study_id>VIGAT-RJ IFNα2b</org_study_id>
    <nct_id>NCT01841775</nct_id>
  </id_info>
  <brief_title>Interferon α 2b Pharmacovigilance Study</brief_title>
  <official_title>Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitário Clementino Fraga Filho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3
      patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks,
      and the verification of sustained virological response at week 48.

      The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic
      Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health:

      http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Diary for recording adverse events by patients daily;
Monthly follow-up interview with MD and PharmD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>24 weeks after finishing treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">85</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon α 2b + ribavirin</intervention_name>
    <description>interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks
ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genotype 2/3 Chronic Hepatitis C confirmed by biomolecular technology (RNAVHC);

          -  Treatment naive;

          -  Signing the Informed Consent Form;

          -  Eligibility criteria and outcome measures followed the Clinical Protocol and
             Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of
             Health:
             http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf

        Exclusion Criteria:

          -  Serious adverse events;

          -  Intolerance to treatment;

          -  Lost to follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliane M. dos Santos, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paulo Roberto G. dos Santos, PharmD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah A. da Conceição, BScN</last_name>
    <role>Study Director</role>
    <affiliation>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitário Clementino Fraga Filho (Clementino Fraga Filho University Hospital)</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21041-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.bio.fiocruz.br</url>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Genotype 2/3</keyword>
  <keyword>Interferon α 2b</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Pharmacovigilance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

